Malignant hyperthermia – state of knowledge
Malignant hyperthermia (MH) is a relatively rare, but potentially lethal genetic disorder. That disease is characterized by hypermetabolic response of the skeletal muscles caused by exposure to triggering agents e.g. volatile anesthetics or depolarizing neuromuscular blockers. The object of this...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2022-09-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/40023 |
| _version_ | 1798000529287151616 |
|---|---|
| author | Michał Perszke Dominika Egierska Kamil Cieślak Miłosz Berliński Witold Świenc Oskar Tokarczuk Anna Walendzik |
| author_facet | Michał Perszke Dominika Egierska Kamil Cieślak Miłosz Berliński Witold Świenc Oskar Tokarczuk Anna Walendzik |
| author_sort | Michał Perszke |
| collection | DOAJ |
| description |
Malignant hyperthermia (MH) is a relatively rare, but potentially lethal genetic disorder. That disease is characterized by hypermetabolic response of the skeletal muscles caused by exposure to triggering agents e.g. volatile anesthetics or depolarizing neuromuscular blockers.
The object of this article was to review and assess the most recent published works about the epidemiology, etiology, pathomechanism, therapy of the MH and the new advances in all these fields.
Authors scrutinized PubMed and Google Scholar using keywords: malignant hyperthermia, volatile anesthetics, ryanodine receptor mutation. In addition to this, the references of chosen articles were manually scoured for supplementary applicable articles. The literature was selected on the basis of a general medicine readership and prioritized clinical practice guidelines, systematic reviews and case reports.
The references include the latest reports on malignant hyperthermia, apart from works of historical importance.
Available treatment methods consist mainly of pharmacotherapy, symptomatic treatment and monitoring of vital parameters. Dantrolene is a first-choice drug in initial treatment of MH and is considered the only specific antidote.
In spite of the constant advances in the areas of medicine there is still much to be discovered about MH. Further studies are necessary, as the amount of credible evidence is not adequate.
|
| first_indexed | 2024-04-11T11:21:44Z |
| format | Article |
| id | doaj.art-7af115feb0974d799e3904f17e86fb9b |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-11T11:21:44Z |
| publishDate | 2022-09-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-7af115feb0974d799e3904f17e86fb9b2022-12-22T04:26:59ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062022-09-0112910.12775/JEHS.2022.12.09.102Malignant hyperthermia – state of knowledgeMichał Perszke0Dominika Egierska1Kamil Cieślak2Miłosz Berliński3Witold Świenc4Oskar Tokarczuk5Anna Walendzik6Uniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we WrocławiuUniwersytet Medyczny im. Piastów Śląskich we Wrocławiu Malignant hyperthermia (MH) is a relatively rare, but potentially lethal genetic disorder. That disease is characterized by hypermetabolic response of the skeletal muscles caused by exposure to triggering agents e.g. volatile anesthetics or depolarizing neuromuscular blockers. The object of this article was to review and assess the most recent published works about the epidemiology, etiology, pathomechanism, therapy of the MH and the new advances in all these fields. Authors scrutinized PubMed and Google Scholar using keywords: malignant hyperthermia, volatile anesthetics, ryanodine receptor mutation. In addition to this, the references of chosen articles were manually scoured for supplementary applicable articles. The literature was selected on the basis of a general medicine readership and prioritized clinical practice guidelines, systematic reviews and case reports. The references include the latest reports on malignant hyperthermia, apart from works of historical importance. Available treatment methods consist mainly of pharmacotherapy, symptomatic treatment and monitoring of vital parameters. Dantrolene is a first-choice drug in initial treatment of MH and is considered the only specific antidote. In spite of the constant advances in the areas of medicine there is still much to be discovered about MH. Further studies are necessary, as the amount of credible evidence is not adequate. https://apcz.umk.pl/JEHS/article/view/40023malignant hyperthermiaryanodine receptorsuccinylocholineanesthetics |
| spellingShingle | Michał Perszke Dominika Egierska Kamil Cieślak Miłosz Berliński Witold Świenc Oskar Tokarczuk Anna Walendzik Malignant hyperthermia – state of knowledge Journal of Education, Health and Sport malignant hyperthermia ryanodine receptor succinylocholine anesthetics |
| title | Malignant hyperthermia – state of knowledge |
| title_full | Malignant hyperthermia – state of knowledge |
| title_fullStr | Malignant hyperthermia – state of knowledge |
| title_full_unstemmed | Malignant hyperthermia – state of knowledge |
| title_short | Malignant hyperthermia – state of knowledge |
| title_sort | malignant hyperthermia state of knowledge |
| topic | malignant hyperthermia ryanodine receptor succinylocholine anesthetics |
| url | https://apcz.umk.pl/JEHS/article/view/40023 |
| work_keys_str_mv | AT michałperszke malignanthyperthermiastateofknowledge AT dominikaegierska malignanthyperthermiastateofknowledge AT kamilcieslak malignanthyperthermiastateofknowledge AT miłoszberlinski malignanthyperthermiastateofknowledge AT witoldswienc malignanthyperthermiastateofknowledge AT oskartokarczuk malignanthyperthermiastateofknowledge AT annawalendzik malignanthyperthermiastateofknowledge |